These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16683418)

  • 1. The FDA and the person with cancer: give PROs a chance.
    Cella D
    Oncology (Williston Park); 2006 Apr; 20(4):436. PubMed ID: 16683418
    [No Abstract]   [Full Text] [Related]  

  • 2. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 3. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 4. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 5. External influences on protocol design.
    Spilker B
    Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
    [No Abstract]   [Full Text] [Related]  

  • 6. Patients, physicians, and clinical trials: the other side of the coins.
    Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
    J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
    [No Abstract]   [Full Text] [Related]  

  • 7. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 9. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 11. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient.
    Basch E; Geoghegan C; Coons SJ; Gnanasakthy A; Slagle AF; Papadopoulos EJ; Kluetz PG
    JAMA Oncol; 2015 Jun; 1(3):375-9. PubMed ID: 26181187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer nanotherapeutics in clinical trials.
    Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
    Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 16. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
    Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
    [No Abstract]   [Full Text] [Related]  

  • 18. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 19. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA says it's open to new approaches to cancer trials.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):795, 800. PubMed ID: 18436724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.